Recursion Pharmaceuticals

New York, United States Founded: 2013 • Age: 13 yrs
Novel therapeutics are discovered using an AI-enabled drug platform.
Annual revenue $58.8M Latest available
Total funding $456.7M 21 rounds
Employees - Tracked headcount
Investors 35 Known backers
Products 3 Services tracked
Competitors 7 Brand Intelligence

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is a company based in New York (United States) founded in 2013. Recursion Pharmaceuticals has raised $456.66 million across 21 funding rounds from investors including Nvidia, Intermountain Healthcare and Bayer. Recursion Pharmaceuticals has completed 4 acquisitions, including Cyclica, Exscientia and Valence Labs. Recursion Pharmaceuticals offers products and services including BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform. Recursion Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Moderna, C4 Therapeutics and Spark Therapeutics, among others.

  • Headquarter New York, United States
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Recursion Pharmaceuticals, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $58.84 M (USD)
    32
    as on Dec 31, 2024
  • Net Profit
    -$463.66 M (USD)
    -41.33
    as on Dec 31, 2024
  • EBITDA
    -$442.51 M (USD)
    -39.33
    as on Dec 31, 2024
  • Total Equity Funding
    $456.66 M (USD)

    in 21 rounds

  • Latest Funding Round
    $6 M (USD), Seed

    Feb 29, 2024

  • Investors
    Nvidia

    & 34 more

  • Employee Count
    Not available
  • Investments & Acquisitions
    Cyclica

    & 3 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Recursion Pharmaceuticals

Recursion Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol RXRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: RXRX · Sector: Health technology · USA

Products & Services of Recursion Pharmaceuticals

Recursion Pharmaceuticals offers a comprehensive portfolio of products and services, including BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform.

Product name locked
Category locked
Primary

Supercomputer for processing large-scale biological and chemical data.

Product name locked
Category locked
Locked

AI agent for drug discovery processes and data analysis.

Product name locked
Category locked
Locked

Integrated platform for AI-enabled gene and compound profiling.

People of Recursion Pharmaceuticals

Headcount 200-500
Employee Profiles 143
Board Members and Advisors 9
Employee Profiles
People
Kristen Rushton
VP, Project Management & Chief of Staff
People
Matt Kinn
VP, Business Development & Corporate Initiatives
People
Jody Barbeau
Director, Scientific Communications
People
Fraser Cunningham
Associate Director, Medicinal Chemistry (drug Design)

Unlock access to complete

Board Members and Advisors
people
Alaa Saleh Halawa
Board Observer
people
Robert Hershberg
Board Member
people
Lee Cooper
Board Observer
people
Blake Borgeson
Board Member

Unlock access to complete

Funding Insights of Recursion Pharmaceuticals

Recursion Pharmaceuticals has successfully raised a total of $456.66M across 21 strategic funding rounds. The most recent funding activity was a Seed round of $6 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Recursion Pharmaceuticals

Recursion Pharmaceuticals has secured backing from 35 investors, including institutional and venture fund investors. Prominent investors backing the company include Nvidia, Intermountain Healthcare and Bayer.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are directed toward multiple sectors by Kinnevik.
Locked Locked Locked
Venture capital firm investing in life sciences sector
Locked Locked Locked
Investing in Life Sciences sectors like Healthcare and Biotechnology.
Locked Locked Locked
Premium access

Investor details for Recursion Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Recursion Pharmaceuticals

Recursion Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cyclica, Exscientia and Valence Labs.

Investments
Premium access

Investment portfolio details for Recursion Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Research and productization engine within Recursion that focuses on advancing the frontier of AI in drug discovery
Locked Locked 2017 Locked
Provider of living informatics platform for preclinical in vivo drug research
Locked Locked 2013 Locked
AI-driven drug discovery and precision medicine solutions are provided.
Locked Locked 2012 Locked
Premium access

Complete acquisition details for Recursion Pharmaceuticals

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Recursion Pharmaceuticals

Premium access

Detailed financials for Recursion Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Recursion Pharmaceuticals Comparisons

Recursion Pharmaceuticals Primary company
Description
Novel therapeutics are discovered using an AI-enabled drug p...
Location
New York, United States
Founded Year
2013
Annual Revenue
$58.84 M (USD)
Net Profit
-$463.66 M (USD)
EBITDA
-$442.51 M (USD)
Employees
Not available
Premium access

Peer comparison for Recursion Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Recursion Pharmaceuticals

Recursion Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Moderna, C4 Therapeutics and Spark Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Premium access

Detailed competitors of Recursion Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Recursion Pharmaceuticals

Premium access

Complete news archive for Recursion Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Recursion Pharmaceuticals

Recursion Pharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Recursion Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.

Recursion Pharmaceuticals is a funded company, having raised a total of $456.66M across 21 funding rounds to date.

Annual revenue of Recursion Pharmaceuticals is $58.84M as on Dec 31, 2024.

Recursion Pharmaceuticals was founded in 2013 and is headquartered in New York, United States. Operations center on biotechnology, where an AI platform is applied to drug discovery and development. Biological and chemical datasets are analyzed alongside machine learning models and a supercomputer to identify targets and design molecules. Emphasis is given to conditions with unmet needs, including cancers and rare diseases. Strategic partnerships are pursued to broaden therapeutic applications.

Recursion Pharmaceuticals's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.

Recursion Pharmaceuticals offers BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform.

Yes, Recursion Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol RXRX.

Recursion Pharmaceuticals has made 4 acquisitions, including Cyclica, Exscientia, and Valence Labs.

Recursion Pharmaceuticals has 35 investors. Key investors include Nvidia, Intermountain Healthcare, Bayer, NIH, and Square 1 Bank.

The ticker symbol of Recursion Pharmaceuticals is RXRX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available